

Cost-effectiveness of alendronate and zoledronic acid in osteoporosis treatment: a systematic review

Pham Nu Hanh Van¹, Nguyen Thanh Binh¹, Dang Hong Hoa², Nguyen Van Tuan^{3,4}
¹Hanoi University of Pharmacy, ²Department of Musculoskeletal Diseases, E Hospital, ³Garvan Institute of Medical Research, Sydney, Australia, ⁴New South Wales University, Sydney, Australia

Summary: Osteoporosis affects both men and women, with the latter group having a higher risk than the former. The objective of this study was to identify and summarize recent studies to evaluate the cost-effectiveness of Alendronat and acid Zoledronic, the two most commonly used drugs in Vietnam. The research followed the guidance of Cochrane systematic review and based on Pubmed database. 10 studies were included in the analysis. Study characteristics and ICER data was extracted and analysed. When compared with no treatment, both drugs is generally cost-effective with a threshold of above 45,000 €/QALY in age from 60-65 year women, especially in people with a previous fracture. Key drivers of cost-effectiveness included history of fracture, fracture risk, rate of adherence and payment threshold.